IDEAYA Biosciences, Inc. (IDYA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-438.0%

-$106.93

vs $31.64 price

Levered DCF

-$122.43

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

14.74

Safe zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-27.01×	-7.65×	-18.15×	-12.8×	-16.77×	-10.69×	-3.95×	-4.64×
P/B	2.99×	1.98×	3.3×	2.15×	2.76×	1.75×	1.51×	-3.26×
P/S	13.99×	299.88×	87.52×	14.79×	29.83×	17.71×	0×	0×
EV / EBITDA	-19.22×	-7.52×	-17.37×	-12.16×	-15.54×	-8.48×	-3.06×	-4.15×
Gross margin	-43.9%	45.2%	82.9%	95.9%	93.8%	92.9%	0.0%	0.0%
Operating margin	-72.8%	-4671.1%	-574.9%	-122.7%	-179.9%	-180.9%	0.0%	0.0%
Net margin	-52.0%	-3921.1%	-483.0%	-115.2%	-178.1%	-176.6%	0.0%	0.0%
Current ratio	11.34×	14.97×	19.65×	11.68×	5.56×	7.47×	14.65×	16.75×
Debt / equity	0.03×	0.02×	0×	0.01×	0.02×	0.03×	0.07×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-11.1%	-25.9%	-18.2%	-16.8%	-16.5%	-17.4%	-41.8%	70.2%
Return on invested capital	-15.2%	-30.3%	-21.5%	-17.5%	-14.9%	-13.5%	-41.3%	-40.0%
Return on assets	-10.2%	-24.4%	-17.4%	-15.1%	-13.0%	-11.6%	-37.1%	-35.6%
Free cash flow yield	-2.4%	-12.0%	-5.7%	-12.0%	-7.0%	15.9%	-26.8%	-18.4%
Earnings yield	-3.7%	-13.1%	-5.5%	-7.8%	-6.0%	-10.0%	-27.7%	-21.6%
Enterprise value	$3B	$2B	$1.9B	$687.9M	$746.5M	$280.8M	$124.5M	$138.9M
Net debt / EBITDA	0.55×	0.24×	1.41×	1.15×	1.81×	1.97×	0.67×	0.61×
Cash conversion cycle (days)	-10	-1,468	-601	-742	-430	-217	-208	-584